(Q35244295)

7 August 2017

title

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164 (English)

1 reference

7 August 2017

main subject

opportunistic infection

1 reference

Elena Losina

8

0 references

William G Powderly

object named as

William Powderly

7

0 references

Kenneth A. Freedberg

9

object named as

Kenneth A Freedberg

1 reference

7 August 2017

1

Paul E Sax

1 reference

7 August 2017

3

Bruce R Schackman

1 reference

7 August 2017

Caroline E Sloan

2

1 reference

7 August 2017

Philip M Grant

4

1 reference

7 August 2017

Jian Rong

5

1 reference

7 August 2017

Andrew R Zolopa

6

1 reference

7 August 2017

Cepac US And Actg A5164 Investigators

10

1 reference

7 August 2017

language of work or name

1 reference

1 September 2010

1 reference

7 August 2017

1 reference

7 August 2017

volume

11

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

248-259

1 reference

Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Maraviroc for previously treated patients with R5 HIV-1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Raltegravir with optimized background therapy for resistant HIV-1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS.

12 July 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Hospital-wide code rates and mortality before and after implementation of a rapid response team

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

The effect of a rapid response team on major clinical outcome measures in a community hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Late HIV testing - 34 states, 1996-2005.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

The cost effectiveness of combination antiretroviral therapy for HIV disease.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3183461

Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study

26 September 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-248

Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21126955

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1310/HCT1105-248

1 reference

7 August 2017

1 reference

7 August 2017

1 reference